IgE-class–specific immunosuppression in offspring by administration of anti-IgE to pregnant mice

Induction of high titers of anti-IgE by immunization of inbred mice with syngeneic IgE.

We have generated high titers (up to 1 mg/ml) of antibodies to isotypic determinants of IgE by immunization of A/J mice with syngeneic monoclonal IgE conjugated to keyhole limpet hemocyanin. As much as 3 mg of anti-idiotypic antibodies per ml was induced at the same time. In contrast to conventional rheumatoid factors, the anti-isotypic antibodies are of moderately high affinity (10(7)-10(8) M-...

Inhibition of IgE and IgE/anti-IgE mediated responses in mast cells by Omalizumab

Results Omalizumab (10 ug/mL) inhibited IgE binding to LAD2 cells by 78% (P=0.007) compared to untreated control. Omalizumab (10 ug/mL) further blocked IgE-dependent upregulation of FcεRI expression by 90% (P=0.03). In addition, omalizumab removed FcεRI-bound IgE in a time-dependent manner; an effect that was detected as early as 24 hrs (57% removal; P<0.001) after addition of omalizumab result...

Suppression of IgE B Cells and IgE Binding to Fc RI by Gene Therapy with Single-Chain Anti-IgE

Anti-IgE: beyond asthma

Omalizumab (anti-IgE ab) is a recombinant humanized monoclonal antibody (rhuMAb-E25) developed by immunizing mice with human IgE. Then, a monoclonal antibody was selected that recognizes IgE at the same site as the highaffinity receptor for IgE (FcεRI). Omalizumab is the only Mab to date that has been found to be effective and approved by both the FDA and European Medicines Agency (EMA) for the...

ANTI-Ige: An Overview

Asthma is common chronic inflammatory disease of the airways characterised by variable and attacks of cough and breathlesness, usually precipitated by an enviromental trigger (air pollution, smoke, etc). The prevalence and severity for allergic asthma have increased markedly in the last several decades. Dysregulated expression patterns of proand anti inflammatory mechanisms are thought to be re...